DepoMed, Inc. (NASDAQ:DEPO)
CAPS Rating:
A specialty pharmaceutical company focused on the development and commercialization of differentiated products that address growing markets and are based on proprietary oral drug delivery technologies.
RSS Headlines
Fool UK
Recs
When all the bad news is out and the stock has oversold below $2.50, that's when I bought with real money and expect in 5 years to be more than a 5 bagger.
Just about perfect trade!